Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

IDEAL OPTION, PLLC

NPI: 1538662663 · RENTON, WA 98057 · Clinical Medical Laboratory · NPI assigned 03/15/2018

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official DAWSON, BRIAN controls 20+ related entities in our dataset. Read more

$165K
Total Medicaid Paid
604
Total Claims
507
Beneficiaries
5
Codes Billed
2018-10
First Month
2024-11
Last Month

Provider Details

Authorized OfficialDAWSON, BRIAN (CMO)
NPI Enumeration Date03/15/2018

Related Entities

Other providers sharing the same authorized official: DAWSON, BRIAN

ProviderCityStateTotal Paid
IDEAL OPTION, PLLC KENNEWICK WA $39.28M
IDEAL OPTION, PLLC HAGERSTOWN MD $7.35M
IDEAL OPTION, PLLC CUT BANK MT $3.65M
IDEAL OPTION, PLLC GREAT FALLS MT $3.29M
COLORADO HOSPITALIST SERVICES, PLLC ENGLEWOOD CO $2.21M
IDEAL OPTION, PLLC CUMBERLAND MD $1.79M
IDEAL OPTION, PLLC BOZEMAN MT $1.62M
EAGLE CREEK EMERGENCY GROUP, PC PARIS TN $1.42M
IDEAL OPTION LAB KENNEWICK WA $1.32M
IDEAL OPTION, PLLC BILLINGS MT $1.16M
IDEAL OPTION, PLLC FREDERICK MD $1.06M
IDEAL OPTION, PLLC WALDORF MD $917K
IDEAL OPTION, PLLC KALISPELL MT $731K
IDEAL OPTION, PLLC HELENA MT $702K
IDEAL OPTION, PLLC HELENA MT $695K
IDEAL OPTION, PLLC WILLISTON ND $691K
IDEAL OPTION, PLLC GREAT FALLS MT $676K
IDEAL OPTION, PLLC BUTTE MT $620K
IDEAL OPTION, PLLC CATONSVILLE MD $590K
HAVELY SPRINGS EMERGENCY GROUP, PC SPRINGFIELD TN $584K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 120 $15K
2020 64 $2K
2022 59 $1K
2023 308 $145K
2024 53 $2K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
H0001 Alcohol and/or drug assessment 253 249 $144K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 66 55 $9K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 207 138 $5K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 18 18 $4K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 60 47 $3K